Compliance Rate
Compliance Rate
0%
Compliant submissions
0
Incompliant submissions
0
Total trials
0
My Organizations' Clinical Trials
Showing 2 of 2 entries
View as:
Phase: N/A
Priority: Normal
Start: 02/28/15
End: 05/18/20
Due: 05/18/21
Phase: N/A
Priority: Normal
Start: 10/01/17
End: 12/31/21
Due: 12/31/22
| Title | NCT ID | Organization | User | Status | Start Date | End Date | Reporting Due Date | Last Checked | User Role | Org Created |
|---|---|---|---|---|---|---|---|---|---|---|
| Procaspase Activating Compound-1 (PAC-1) in the Treatment of Advanced Malignancies - Component 1 | NCT02355535 | Vanquish Oncology, Inc. | user2@example.com | None | 2015-02-28 | 2020-05-18 | 2021-05-18 | - | - | 2025-07-14 |
| Procaspase Activating Compound-1 (PAC-1) in the Treatment of Advanced Malignancies - Component 2 | NCT03332355 | Vanquish Oncology, Inc. | user2@example.com | None | 2017-10-01 | 2021-12-31 | 2022-12-31 | - | - | 2025-07-14 |